Investigating the Role of Lymph Nodes in Lung Cancer with Pleural Invasion
Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion
This study is trying to see if checking certain lymph nodes can help doctors better understand and treat patients with non-small cell lung cancer that has spread to the pleura.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 958 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Luzerner Kantonsspital Academic / other |
| Locations | 1 site (Lucerne) |
| Trial ID | NCT05596578 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the significance of intrapulmonary lymph nodes in patients diagnosed with non-small cell lung cancer (NSCLC) who have visceral pleural invasion. It focuses on understanding whether the dissection of specific lymph nodes is necessary for accurate staging and treatment planning. The study will analyze samples from lymph node stations 12, 13, and 14 to assess their prognostic value. The research seeks to clarify the controversial impact of visceral pleural invasion on patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients undergoing anatomical resection for NSCLC tumors smaller than 3 cm with visceral pleural invasion.
Not a fit: Patients with prior lung cancer, advanced disease (pN2 or M1), or those who have undergone neoadjuvant treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve staging accuracy and treatment strategies for patients with NSCLC, potentially leading to better outcomes.
How similar studies have performed: While the significance of lymph node dissection in NSCLC is debated, this specific approach to studying intrapulmonary lymph nodes is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Anatomical resection for NSCLC \<3 cm (lobectomy, bilobectomy, segmentectomy) * Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes * Resection of lymphnodes station 10 and 11 during hilar separation. * R0 resection Exclusion Criteria: * Prior or synchronous lung cancer * pN2 * Pneumonectomy * R1/R2 resection * M1 * Neoadjuvant treatment
Where this trial is running
Lucerne
- Kantonsspital Luzern — Lucerne, Switzerland (Recruiting)
Study contacts
- Study coordinator: Fabrizio Minervini, MD, PhD
- Email: fabriziominervini@hotmail.com
- Phone: +410412051111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.